MedTrace Logo

Study of NGM313 in Obese Participants

NCT03298464 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-03-13

No results posted yet for this study

Summary

The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants

Conditions

Interventions

BIOLOGICAL

NGM313

Subcutaneous injection

DRUG

Pioglitazone

White to off-white round tablet

Sponsors & Collaborators

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-11
Primary Completion
2018-06-19
Completion
2018-07-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03298464 on ClinicalTrials.gov